drugset / Trial / NCT04294056

A Study to Evaluate the Differences in Pharmadynamics, Pharmacokinetics, and Safety Between Ciprofol and Propofol

NCT04294056

Phase 1 Completed 18 enrolled Haisco Pharmaceutical Group Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

This is a single-center, open-label, randomized, two-stage, two-way crossover Phase I study in healthy male subjects.The main objective is to evaluate the differences in pharmadynamics (PD), pharmacokinetics (PK), and safety between ciprofol injectable emulsion and propofol injectable emulsion at different doses in healthy subjects.

Timeline

Start
2020-05-26
Primary completion
2020-06-22
Completion
2020-09-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Cipepofol Small molecule 0.4 mg/kg
Subject Cipepofol Small molecule 0.6 mg/kg
Subject Cipepofol Small molecule 0.8 mg/kg
Comparator Propofol Small molecule 2 mg/kg
Comparator Propofol Small molecule 3 mg/kg
Comparator Propofol Small molecule 4 mg/kg

Indications

No indication recorded.